利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

74 records (took 0.031 seconds)

    알킬 술포숙시네이트 혼합물, 및 이의 용도
    1.
    发明公开
    알킬 술포숙시네이트 혼합물, 및 이의 용도 审中-实审
    烷基硫酸盐混合物及其用途

    公开(公告)号：KR1020160113743A

    公开(公告)日：2016-09-30

    申请号：KR1020167026045

    申请日：2009-10-15

    Applicant: 코그니스 아이피 매니지먼트 게엠베하

    Inventor： 벨러안스가르 ,  에스쿠헨라이너 ,  폴게알무트 ,  곤데크헬가 ,  바이홀트카테리네

    IPC: C07C309/17 ,  A61K31/255 ,  A61K8/46 ,  A61Q1/02

    CPC classification number: A61K8/06 ,  A61K8/062 ,  A61K8/064 ,  A61K8/466 ,  A61K2800/596 ,  A61Q1/02 ,  A61Q1/06 ,  A61Q5/065 ,  A61Q5/10 ,  A61Q15/00 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/08 ,  C07C309/17 ,  A61K8/46 ,  A61K31/255

    Abstract: 본발명은하기화학식 (I) 및/또는 (II) (식중, R 은 6 내지 22 개의탄소원자를갖는선형또는분지형, 포화또는불포화알킬라디칼이고, X 및 Y 는각각독립적으로수소원자, 또는수용성염을형성할수 있고알칼리금속, 알칼리토금속, 암모니아및 유기암모니아로이루어지는군으로부터선택되는양이온임) 의알킬술포숙시네이트모노에스테르의혼합물에관한것이다.본발명은혼합물이 30 내지 70 중량% 의 C16 알킬술포숙시네이트모노에스테르및 30 내지 70 중량% 의 C18 알킬술포숙시네이트모노에스테르를함유하는것을특징으로하며, 이때중량% 는화학식 (I) 및 (II) 의알킬술포숙시네이트모노에스테르의총량에대한것이다. 본발명은또한미용및/또는약학제제에서의상기혼합물의용도에관한것이다.

    Abstract translation: 本发明涉及通式（I）和/或（II）的烷基磺基琥珀酸单酯的混合物，其中R表示具有6至22个C原子的直链或支链，饱和或不饱和的烷基，X和Y独立地表示 氢原子或可形成水溶性盐的阳离子，选自碱金属，碱土金属，氨，有机氨等。 本发明的特征在于，该混合物含有30至70重量％的C16烷基磺基琥珀酸酯单酯和30至70重量％的C 18烷基磺基琥珀酸酯单酯，其重量百分比相对于式（I）的磺基琥珀酸烷基酯单体的总量 （I）和（II）。 本发明还涉及所述混合物在化妆品和/或药物制剂中的用途。

    오메가-3 지질 화합물
    5.
    发明公开
    오메가-3 지질 화합물 有权
    新型脂肪化合物

    公开(公告)号：KR1020090112631A

    公开(公告)日：2009-10-28

    申请号：KR1020097011327

    申请日：2007-11-01

    Applicant: 프로노바 바이오파마 너지 에이에스

    Inventor： 홀메이드,앤,크리스틴 ,  로스맨,제니

    IPC: C07C69/587 ,  A61K31/22 ,  C07F9/113 ,  C07C309/67

    CPC classification number: C07H15/04 ,  A23D9/00 ,  A61K31/045 ,  A61K31/047 ,  A61K31/075 ,  A61K31/10 ,  A61K31/22 ,  A61K31/225 ,  A61K31/232 ,  A61K31/255 ,  A61K31/265 ,  A61K31/661 ,  A61K45/06 ,  A61K49/0004 ,  C07C57/03 ,  C07C57/12 ,  C07C69/007 ,  C07C69/24 ,  C07C69/40 ,  C07C69/587 ,  C07C69/96 ,  C07C211/20 ,  C07C229/30 ,  C07C305/14 ,  C07C323/14 ,  C07C323/54 ,  C07F9/091 ,  C07F9/106 ,  C07F9/113 ,  A61K2300/00

    Abstract: Omega-3 lipid compounds of the general formula (I): wherein R1 and R2are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a carboxy group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; P represents a hydrogen atom, (Formula II) wherein P2, P3, and P4 are chosen from a hydrogen atom, an alkyl group, and a C14-C22 alkenyl group, wherein the alkyl and alkenyl groups are optionally substituted with a hydroxy group, (Formula III), (Formula IV), or (Formula V); and Y is a C14-C22 alkenyl group with at least one double bond, having E and/or Z configuration; or any pharmaceutically acceptable complex, solvate, salt or pro-drug thereof, with the proviso that R1 and R2 are not simultaneously a hydrogen atom. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments, in particular for the treatment of cardiovascular and metabolic diseases.

    Abstract translation: 通式（I）的ω-3脂质化合物：其中R 1和R 2相同或不同，并且选自氢原子，羟基，烷基，卤素原子，烷氧基，酰氧基， 酰基，烯基，炔基，芳基，烷硫基，烷氧基羰基，羧基，烷基亚磺酰基，烷基磺酰基，氨基和烷基氨基; P表示氢原子，（式II）其中P2，P3和P4选自氢原子，烷基和C14-C22烯基，其中烷基和烯基任选被羟基取代， （式III），（式IV）或（式V）; Y是具有至少一个具有E和/或Z构型的双键的C 14 -C 22烯基; 或其任何药学上可接受的络合物，溶剂合物，盐或前药，条件是R1和R2不同时为氢原子。 还公开了包含这些化合物的药物组合物和脂质组合物，以及用作药物的这种化合物，特别是用于治疗心血管和代谢疾病。

    점막 내층의 생물물리학적 특성의 변화를 위한 제제
    6.
    发明公开
    점막 내층의 생물물리학적 특성의 변화를 위한 제제 无效
    用于改变粘膜内衬生物学特性的配方

    公开(公告)号：KR1020080018872A

    公开(公告)日：2008-02-28

    申请号：KR1020077027567

    申请日：2006-05-18

    Applicant: 풀매트릭스 오퍼레이팅 컴퍼니, 인크

    Inventor： 와타나베,위위크 ,  토마스,매튜 ,  카트스트라,제프리 ,  클라케,로버트

    IPC: A61K9/12 ,  A61K9/08 ,  A61K9/00

    CPC classification number: A61K33/14 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0048 ,  A61K9/007 ,  A61K9/0078 ,  A61K31/255 ,  A61K31/721 ,  A61K47/02 ,  A61K47/12 ,  Y02A50/475

    Abstract: Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may optionally be included with the formulation. The active agent may be administered with or incorporated into the formulation, or may be administered after the conductive formulation is administered. When applied to mucosal lining fluids, the formulation alters the physical properties such as the surface tension, surface elasticity, and bulk viscosity of the mucosal lining. The formulation is administered in an amount sufficient to alter biophysical properties in the mucosal linings of the body. The formulations may be administered for several different purposes: reducing the spreading of infectious diseases, both viral and bacterial, such as SARS, influenza, tuberculosis, and RSV in humans and hoof and mouth disease in cloven-footed animals; minimizing ambient contamination due to particle formation during breathing, coughing, sneezing, or talking which is particularly important in the clean room applications; decreasing or preventing the occurrence of obstructive sleep apnea and some cases of irritable bowel syndrome; and controlling the uptake kinetics of drug molecules and pathogens.

    Abstract translation: 已经开发了含有导电剂，例如盐，离子表面活性剂或处于电离状态或容易在水溶液或有机溶剂环境中离子化的其它物质的导电配方，以及使用方法。 制剂中可以任选地包括一种或多种活性剂，例如抗病毒剂，抗微生物剂，抗炎剂，蛋白质或肽。 活性剂可以与制剂一起施用或掺入制剂中，或者可以在施用导电制剂后施用。 当施用于粘膜衬里液时，制剂会改变物理性质，如粘膜内衬的表面张力，表面弹性和体积粘度。 该制剂的施用量足以改变身体粘膜内衬的生物物理性质。 制剂可以用于几种不同的目的：减少病毒和细菌感染性疾病如SARS，流行性感冒，结核病和RSV在人类中的扩散，以及在六足动物中的蹄和口腔疾病; 在洁净室应用中特别重要的是在呼吸，咳嗽，打喷嚏或说话期间由于颗粒形成造成的环境污染最小化; 减少或预防阻塞性睡眠呼吸暂停和一些肠易激综合征的发生; 并控制药物分子和病原体的吸收动力学。

    종양, 종양 관련 질환 및 악액질의 치료 및 예방 방법 및조성물
    10.
    发明公开
    종양, 종양 관련 질환 및 악액질의 치료 및 예방 방법 및조성물 失效
    用于治疗和预防肿瘤，肿瘤相关疾病和慢性丙型肝炎的药物组合物

    公开(公告)号：KR1020040025927A

    公开(公告)日：2004-03-26

    申请号：KR1020040010953

    申请日：2004-02-19

    Applicant: 상꾜 가부시키가이샤

    Inventor： 구라까따신이찌 ,  하나이마사하루 ,  가나이사오리 ,  기무라도미오

    IPC: A61K31/40 ,  A61P3/00

    CPC classification number: A61K31/541 ,  A61K31/10 ,  A61K31/18 ,  A61K31/255 ,  A61K31/341 ,  A61K31/351 ,  A61K31/352 ,  A61K31/365 ,  A61K31/40 ,  A61K31/402 ,  A61K31/415 ,  A61K31/42 ,  A61K31/421 ,  A61K31/425 ,  A61K31/5415

    Abstract: PURPOSE: Pharmaceutical compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia are provided, thereby effectively treating and preventing tumors and tumor-related disorders and cachexia by certain cyclooxygenase-2 inhibitors. CONSTITUTION: The pharmaceutical compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia comprises a compound of formula (I),(II) and pharmaceutically acceptable salts thereof, wherein R represents a hydrogen atom, a halogen atom or a lower alkyl group; R1 represents a lower alkyl group, an amino group or a group of formula -NHRa in which Ra represents a group which may be eliminated in vivo; R2 represents a phenyl group or a phenyl group which is substituted by at least one of substituents alpha or substituents beta , defined below; R3 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkyl group which is substituted by at least one of substituents alpha ; R4 represents a hydrogen atom, a lower alkyl group, a lower alkyl group which is substituted by at least one of substituents alpha, a cycloalkyl group, an aryl group.

    Abstract translation: 目的：提供用于治疗和预防肿瘤，肿瘤相关疾病和恶病质​​的药物组合物，从而有效地治疗和预防某些环加氧酶-2抑制剂的肿瘤和肿瘤相关疾病和恶病质​​。 构成：用于治疗和预防肿瘤，肿瘤相关疾病和恶病质​​的药物组合物包含式（I），（II）及其药学上可接受的盐的化合物，其中R表示氢原子，卤素原子或低级 烷基; R1表示低级烷基，氨基或式-NHRa基团，其中Ra表示可在体内被除去的基团; R 2表示苯基或被至少一个下列定义的取代基α或取代基β取代的苯基; R3表示氢原子，卤素原子，低级烷基或被至少一个取代基α取代的低级烷基; R4表示氢原子，低级烷基，被取代基α，环烷基，芳基中的至少一个取代的低级烷基。

Patent Agency Ranking